SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 75 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $18,407,701 | +17.8% | 1,267,748 | +69.9% | 0.00% | +33.3% |
Q2 2023 | $15,621,838 | +50.7% | 746,385 | +52.1% | 0.00% | +50.0% |
Q1 2023 | $10,365,126 | -7.1% | 490,773 | +12.0% | 0.00% | 0.0% |
Q4 2022 | $11,153,284 | -18.3% | 438,243 | -22.9% | 0.00% | -33.3% |
Q3 2022 | $13,651,000 | +29.9% | 568,081 | +4.0% | 0.00% | +50.0% |
Q2 2022 | $10,510,000 | +48.1% | 546,239 | +33.8% | 0.00% | +100.0% |
Q1 2022 | $7,095,000 | -10.9% | 408,263 | +12.3% | 0.00% | -50.0% |
Q4 2021 | $7,960,000 | +30.1% | 363,661 | +13.6% | 0.00% | +100.0% |
Q3 2021 | $6,117,000 | -66.9% | 320,108 | -70.3% | 0.00% | -75.0% |
Q2 2021 | $18,488,000 | +46.7% | 1,076,768 | +91.1% | 0.00% | +33.3% |
Q1 2021 | $12,602,000 | +2.2% | 563,605 | +1.7% | 0.00% | 0.0% |
Q4 2020 | $12,330,000 | +231.5% | 554,434 | +120.0% | 0.00% | +200.0% |
Q3 2020 | $3,720,000 | -42.6% | 251,970 | -42.4% | 0.00% | -50.0% |
Q2 2020 | $6,483,000 | +3669.2% | 437,462 | +2688.3% | 0.00% | – |
Q1 2020 | $172,000 | -68.4% | 15,689 | -74.7% | 0.00% | – |
Q4 2019 | $545,000 | +220.6% | 62,042 | +172.9% | 0.00% | – |
Q3 2019 | $170,000 | -29.5% | 22,737 | -12.4% | 0.00% | – |
Q2 2019 | $241,000 | +221.3% | 25,968 | +80.7% | 0.00% | – |
Q1 2019 | $75,000 | -68.4% | 14,374 | -73.1% | 0.00% | – |
Q4 2018 | $237,000 | -55.9% | 53,342 | -19.7% | 0.00% | – |
Q3 2018 | $537,000 | +1.9% | 66,399 | -11.6% | 0.00% | – |
Q2 2018 | $527,000 | +125.2% | 75,115 | +357.8% | 0.00% | – |
Q1 2018 | $234,000 | -54.6% | 16,409 | -72.1% | 0.00% | – |
Q4 2017 | $515,000 | +45.9% | 58,747 | +121.7% | 0.00% | – |
Q1 2016 | $353,000 | – | 26,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |